Table 60:
Scenario Analysis Results, nVNS for Acute Treatment, Migraine
| Scenario | Budget impact, $ milliona | |||||
|---|---|---|---|---|---|---|
| Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | Totalb | |
| Reference case | 71.56 | 146.17 | 222.96 | 301.20 | 381.62 | 1,123.52 |
| 1: nVNS provided free for the first 93 days | 11.55 | 23.59 | 35.98 | 48.61 | 61.59 | 734.80 |
| 2: Annual uptake of 2% per year, up to 10% in year 5 | 143.12 | 292.34 | 445.93 | 602.40 | 763.24 | 2,247.03 |
| 3: Annual uptake of 20% per year, up to 100% in year 5 | 1,431.17 | 2,923.45 | 4,459.25 | 6,024.04 | 7,632.43 | 22,470.34 |
| 4a: Cost of the nVNS device decreased by 25% | 53.67 | 109.63 | 167.22 | 225.90 | 286.22 | 842.64 |
| 4b: Cost of the nVNS device increased by 25% | 1,788.96 | 2,654.31 | 5,574.07 | 7,530.05 | 9,540.54 | 28,087.94 |
Abbreviation: nVNS, noninvasive vagus nerve stimulation.
a
In 2024 Canadian dollars.
b
Results may appear inexact due to rounding.